Cytokines modulate telomerase activity in a human multiple myeloma cell line

Cancer Research

Volumn 62, Issue 13, 2002, Pages 3876-3882

  Akiyama, Masaharu ^a   Hideshima, Teru ^a   Hayashi, Toshiaki ^a   Tai, Yu Tzu ^a   Mitsiades, Constantine S ^a   Mitsiades, Nicholas ^a   Chauhan, Dharminder ^a   Richardson, Paul ^a   Munshi, Nikhil C ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; SOMATOMEDIN C; TELOMERASE; WORTMANNIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION;

APOPTOSIS; DEXAMETHASONE; DNA, NEOPLASM; DNA-BINDING PROTEINS; ENZYME INDUCTION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MULTIPLE MYELOMA; RNA, MESSENGER; TELOMERASE; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0036645153     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Multiple myeloma: Increasing evidence for a multistep transformation process
2. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma
3. The development of a model for the homing of multiple myeloma cells to human bone marrow
4. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by IL-6
5. IL-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade
6. Interleukin-6 inhibits apoptosis of malignant plasma cells
7. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase-independent mechanism
8. RAFTK/PYK2-dependent and independent apoptosis in multiple myeloma cells
9. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells
10. Apaf-1/cytochrome c independent and Smac dependent induction of apoptosis in multiple myeloma cells
11. The phosphatidylinositol 3-kinase/Akt kinase pathway in multiple myeloma plasma cells: Role in cytokine-dependent survival and proliferative responses
12. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
13. Insulin-like growth factor I regulates pro-B cell differentiation
14. Insulin-like growth factor I is a growth and survival factor in multiple myeloma cell lines
15. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth
16. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway
17. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
18. Apoptotic signaling induced by immunomodulatory thalidomidev analogs (IMiDs) in human multiple myeloma cells: Therapeutic implications
19. Swithing and signaling at the telomere
20. Telomeres, aging, and cancer: In search of a happy ending
21. Telomerase is not an oncogene
22. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis
23. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells
24. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death
25. Inhibition of telomerase limits the growth of human cancer cells
26. Activation of NF-κB and up-regulation of intracellular antiapoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications
27. Cellular survival: A play in three Akts
28. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit
29. Biologic sequelae of NF-κB blockade in multiple myeloma: Therapeutic implications
30. NF-κB regulates transcription of the mouse telomerase catalytic subunit
31. NF-κB as a therapeutic target in multiple myeloma
32. Isolation and characterization of human multiple myeloma cell enriched populations
33. Ectopic expression of c-myc fails to overcome down-regulation of telomerase activity induced by herbimycin A, but ectopic hTERT expression overcomes it
34. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase
35. NF-κB is a target of Akt in antiapoptotic PDGF signalling
36. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-κB p65/Re1A subunit
37. Akt suppresses apoptosis by stimulating the transactivation potential of the Rc1A/p65 subunit of NF-κB
38. Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation
39. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
40. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays
41. Telomerase activity in plasma cell dyscrasias
42. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells
43. Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase